"beta 2-Glycoprotein I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 44-kDa highly glycosylated plasma protein that binds phospholipids including CARDIOLIPIN; APOLIPOPROTEIN E RECEPTOR; membrane phospholipids, and other anionic phospholipid-containing moieties. It plays a role in coagulation and apoptotic processes. Formerly known as apolipoprotein H, it is an autoantigen in patients with ANTIPHOSPHOLIPID ANTIBODIES.
| Descriptor ID |
D053482
|
| MeSH Number(s) |
D12.776.124.117 D12.776.395.195
|
| Concept/Terms |
beta 2-Glycoprotein I- beta 2-Glycoprotein I
- beta 2 Glycoprotein I
- Apo H
- Endothelial Cell-Viability Maintaining Factor
- Endothelial Cell Viability Maintaining Factor
- beta(2)GPI
- beta2-Glycoprotein I
- beta2 Glycoprotein I
- EC-VMFa
- EC VMFa
- Anticardiolipin Cofactor
- Cofactor, Anticardiolipin
- Apolipoprotein H
|
Below are MeSH descriptors whose meaning is more general than "beta 2-Glycoprotein I".
Below are MeSH descriptors whose meaning is more specific than "beta 2-Glycoprotein I".
This graph shows the total number of publications written about "beta 2-Glycoprotein I" by people in this website by year, and whether "beta 2-Glycoprotein I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 6 | 6 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 4 | 4 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "beta 2-Glycoprotein I" by people in Profiles.
-
Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus. 2021 Jul; 30(8):1283-1288.
-
Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2019 02; 71(2):281-289.
-
The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017 Sep; 26(10):1051-1059.
-
Influenza vaccination can induce new-onset anticardiolipins but not ß2-glycoprotein-I antibodies among patients with systemic lupus erythematosus. Lupus. 2012 Feb; 21(2):168-74.
-
Apolipoprotein H promoter polymorphisms in relation to lupus and lupus-related phenotypes. J Rheumatol. 2009 Feb; 36(2):315-22.
-
Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost. 2008 Apr; 34(3):256-66.
-
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum. 2008 Mar; 58(3):843-53.
-
Genetics of antiphospholipid syndrome. Curr Rheumatol Rep. 2004 Dec; 6(6):458-62.
-
Single nucleotide polymorphisms in the coding region of the apolipoprotein H (beta2-glycoprotein I) gene and their correlation with the protein polymorphism, anti-beta2glycoprotein I antibodies and cardiolipin binding: description of novel haplotypes and their evolution. Ann Hum Genet. 2004 Jul; 68(Pt 4):285-99.
-
Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol. 2004 Jan; 121(1):142-9.